Anti-Human IL12+IL23 Recombinant Antibody (Briakinumab) (CAT#: TAB-103)

Figure 1 Differential sorting of briakinumab and ustekinumab in FcRn-positive sorting endosomes.

HUVECs were incubated together with 200 μg/mL both briakinumab (labeled with AlexaFluor594) and ustekinumab (labeled with AlexaFluor488) for 20 min at 37 °C, pH 7.3, followed by 20 min chase. At the end of the experiment, cells were fixed and counterstained with a monoclonal antibody directed against FcRn (DVN22) (44) detected by secondary antibodies labeled with AlexaFluor647.

Schoch, A., Kettenberger, H., Mundigl, O., Winter, G., Engert, J., Heinrich, J., & Emrich, T. (2015). Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proceedings of the National Academy of Sciences, 112(19), 5997-6002.

Figure 2 Correlation between in vivo PK parameters and FcRn column elution pHs.

Antibodies were administered as a single i.v. bolus injection of 10 mg/kg to six animals per group. Data points represent the mean ± SD. (A) Blood level curves of briakinumab (orange), ustekinumab (green), mAb 8 (purple), and mAb 9 (blue). (B) Correlation between the terminal half-lives with the FcRn column elution pH.

Schoch, A., Kettenberger, H., Mundigl, O., Winter, G., Engert, J., Heinrich, J., & Emrich, T. (2015). Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proceedings of the National Academy of Sciences, 112(19), 5997-6002.

Figure 3 Pharmacokinetic analysis.

(A) Data reproduction of pharmacokinetic study in hFcRn transgenic mice from Schoch et. al. 17 Only early time points are displayed to highlight initial distribution kinetics of ustekinumab (gray, dashed line) versus briakinumab (black, solid line). (B) Pharmacokinetic study in FcRn KO mice. Each time point represents the average serum concentration for the 3 mice, and these averages were fit for each antibody using a 2 phase non-compartmental decay curve.

Kelly, R. L., Yu, Y., Sun, T., Caffry, I., Lynaugh, H., Brown, M.,... & Wittrup, K. D. (2016, October). Target-independent variable region mediated effects on antibody clearance can be FcRn independent. In MAbs (Vol. 8, No. 7, pp. 1269-1275). Taylor & Francis.

Figure 1 Anti-IL12+IL23 Antibody (TAB-103) in WB

Western blot analysis of TAB-103 was performed with Human IL12 Protein (His Tag, Left) and Human IL23 Protein (His Tag, Right). TAB-103 incubation concentration: 2 ng/μL. The secondary antibody: HRP-Anti-Human IgG (H+L) Lane 1: Reducing Antigen (0.1μg) Lane 2: Reducing Antigen (0.3μg) Lane 3: Reducing Antigen (0.6μg)

Figure 2 Anti-IL12+IL23 Antibody (TAB-103) in ELISA

ELISA analysis of TAB-103 was performed with Human IL12 Protein (His Tag, Left) and Human IL23 Protein (His Tag, Right). The secondary antibody: HRP-goat-Anti-Human IgG (H+L)

Figure 3 Anti-IL12+IL23 Antibody (TAB-103) in Dot Blot

Dot Blot analysis of TAB-103 was performed with Human IL12 Protein (His Tag, Up) and Human IL23 Protein (His Tag, Down). TAB-103 incubation concentration: 2 ng/μL. The secondary antibody: HRP-Anti-Human IgG (H+L)